Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.41 |
| ▸ | ITGB7 | P26010 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11984339 | 0.83 | LMNA (0.49) | MAPK1POLBITGA4ITGB7GAA | |
| SCHEMBL11977390 | 0.83 | MAPK1 (0.63) | MAPK1POLBCYP3A4MEN1KMT2A | |
| SCHEMBL10877160 | 0.80 | SMN1; SMN2 (0.51) | MAPK1HTTCYP3A4MEN1KMT2A | |
| SCHEMBL10877163 | 0.80 | SMN1; SMN2 (0.51) | MAPK1HTTCYP3A4MEN1KMT2A | |
| SCHEMBL23023068 | 0.76 | SIGMAR1 (0.55) | MAPK1POLBCYP3A4MEN1KMT2A | |
| SCHEMBL7041284 | 0.76 | SIGMAR1 (0.55) | MAPK1POLBCYP3A4MEN1KMT2A | |
| SCHEMBL1823141 | 0.76 | SIGMAR1 (0.55) | MAPK1POLBCYP3A4MEN1KMT2A | |
| SCHEMBL8438027 | 0.74 | SIGMAR1 (0.58) | MAPK1CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL9393358 | 0.74 | SIGMAR1 (0.58) | MAPK1CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL8367122 | 0.74 | SIGMAR1 (0.58) | MAPK1CYP3A4MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120209007-A9 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-08-16 | — | — | US | disclosed |
| US-20110319629-A1 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319629-A1 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | ABL1, TYR, CD59 | MAPK1 1709/4885POLB 3975/4885NPSR1 2391/4885 |
| US-20120209007-A9 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | ABL1, TYR, CD59 | MAPK1 1709/4885POLB 3975/4885NPSR1 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.